Incyte (INCY) Consolidated Net Income (2010 - 2026)
Incyte (INCY) reported Consolidated Net Income of $303.3 million for Q1 2026, up 91.73% on a YoY basis from $158.2 million in Q1 2025, and up 1.35% quarter-over-quarter from $299.3 million in Q4 2025.
Incyte (INCY) Consolidated Net Income (2010 - 2026) Analysis & Trends
Incyte has reported Consolidated Net Income for 17 years, with the latest figure at $303.3 million in Q1 2026.
- For the quarter ending Q1 2026, Consolidated Net Income rose 91.73% year-over-year to $303.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (up 6631.44% YoY), and the FY2025 full-year result was $1.3 billion, up 3844.96% from the prior year.
- Consolidated Net Income for Q1 2026 stood at $303.3 million, up from $299.3 million in the prior quarter.
- The five-year high for Consolidated Net Income was $424.2 million in Q3 2025, with the low at -$444.6 million in Q2 2024.
- Historically, Consolidated Net Income has averaged $150.6 million across 5 years, with a median of $169.5 million in 2024.
- The largest YoY upside for Consolidated Net Income was 681.22% in 2024 against a maximum downside of 318.43% in 2024.
- Incyte's Consolidated Net Income stood at $28.5 million in 2022, then jumped by 606.51% to $201.1 million in 2023, then climbed by 0.07% to $201.2 million in 2024, then surged by 48.74% to $299.3 million in 2025, then grew by 1.35% to $303.3 million in 2026.
- The last three Consolidated Net Income figures came in at $303.3 million (Q1 2026), $299.3 million (Q4 2025), and $424.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 303.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 303.33 Mn |
| Dec 31, 2025 | 299.28 Mn |
| Sep 30, 2025 | 424.17 Mn |
| Jun 30, 2025 | 405.00 Mn |
| Mar 31, 2025 | 158.20 Mn |
| Dec 31, 2024 | 201.21 Mn |
| Sep 30, 2024 | 106.46 Mn |
| Jun 30, 2024 | -444.60 Mn |
| Mar 31, 2024 | 169.55 Mn |
| Dec 31, 2023 | 201.08 Mn |
| Sep 30, 2023 | 171.27 Mn |
| Jun 30, 2023 | 203.55 Mn |
| Mar 31, 2023 | 21.70 Mn |
| Dec 31, 2022 | 28.46 Mn |
| Sep 30, 2022 | 112.78 Mn |
| Jun 30, 2022 | 161.43 Mn |
| Mar 31, 2022 | 37.99 Mn |
| Dec 31, 2021 | 563.85 Mn |
| Sep 30, 2021 | 181.77 Mn |
| Jun 30, 2021 | 149.46 Mn |